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Objectives: We aimed to study the safety and efﬁcacy of procalcitonin in guiding blood cultures taking in
critically ill patients with suspected infection.
Methods: We performed a cluster-randomized, multi-centre, single-blinded, cross-over trial. Patients
suspected of infection in whom taking blood for culture was indicated were included. The participating
intensive care units were stratiﬁed and randomized by treatment regimen into a control group and a
procalcitonin-guided group. All patients included in this trial followed the regimen that was allocated to
the intensive care unit for that period. In both groups, blood was drawn at the same moment for a
procalcitonin measurement and blood cultures. In the procalcitonin-guided group, blood cultures were
sent to the department of medical microbiology when the procalcitonin was >0.25 ng/mL. The main
outcome was safety, expressed as mortality at day 28 and day 90.
Results: The control group included 288 patients and the procalcitonin-guided group included 276 pa-
tients. The 28- and 90-day mortality rates in the procalcitonin-guided group were 29% (80/276) and 38%
(105/276), respectively. The mortality rates in the control group were 32% (92/288) at day 28 and 40%
(115/288) at day 90. The intention-to-treat analysis showed hazard ratios of 0.85 (95% CI 0.62e1.17) and
0.89 (95% CI 0.67e1.17) for 28-day and 90-day mortality, respectively. The results were deemed non-
inferior because the upper limit of the 95% CI was below the margin of 1.20.
Conclusion: Applying procalcitonin to guide blood cultures in critically ill patients with suspected
infection seems to be safe, but the beneﬁts may be limited.
Trial registration: ClinicalTrials.gov identiﬁer: ID NCT01847079. Registered on 24 April 2013, retrospec-
tively registered. P.J. van der Geest, CMI 2016;▪:1
© 2016 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology
and Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Critical illness predisposes to bacteraemia, thereby increasing
morbidity and mortality [1,2], particularly when diagnosis and
administration of antibiotics are delayed [3,4]. Indeed, culturing
costs time, and only 15%e25% of blood cultures taken in critically ill
patients suspected of infection prove positive, which suggests a
waste of resources [5]. The use of biomarkers, including procalci-
tonin, has been studied to improve a fast and accurate diagnosis ofpartment of Intensive Care
230, 3015 CE Rotterdam, The
van der Geest).
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iology and Infection (2016), hsepsis and bacteraemia with varying results [4,6e8]. However, we
recently performed a meta-analysis of studies suggesting that a
normal procalcitonin has 96% negative predictive value for bac-
teraemia [9]. Based on nine studies, the area under the receiver
operating characteristic curve of procalcitonin for bacteraemia in
critically ill patients was 0.88 [6,9e17]. The studies included,
however, were relatively small [10e12,15e17] and not primarily
designed to rule out or detect bacteraemia [6,10,12e14]. Never-
theless, a rapidly available and normal procalcitonin might allow
early prediction of negative blood cultures when blood sampling is
clinically indicated for suspicion of infection, and might thereby
avoid unnecessary blood culturing.
In the hypothesis that a normal procalcitonin can be used to
predict absence of bacteraemia in critically ill patients, we aimed toof Clinical Microbiology and Infectious Diseases. This is an open access article under
to guide taking blood cultures in the intensive care unit; a cluster-
ttp://dx.doi.org/10.1016/j.cmi.2016.10.004
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saving blood cultures in critically ill patients in whom taking blood
for culture is clinically indicated because of a suspicion of infection.
We hypothesized that such a strategy can be safely applied in
critically ill patients without increasing morbidity and mortality.
Materials and methods
Patients and study design
We performed a prospective, single-blinded, cluster-random-
ized, cross-over trial, involving the intensive care unit (ICU) of the
Erasmus Medical Centre Rotterdam and the Maasstad hospital
Rotterdam. We conducted this trial between January 2013 and
September 2014. The ICU of the Erasmus Medical Centre is a
tertiary-care mixed medicalesurgery ICU with 2000 admissions
per year. The ICU of the Maasstad Hospital is a secondary-care
mixed medicalesurgical ICU with 1200 annual admissions. The
trial was conducted in accordance with the ethical principles
decreed by the Declaration of Helsinki and in compliance with the
International Conference on Harmonization of Good Clinical Prac-
tice Guidelines. The ﬁnal protocol, amendments and informed
consent document were reviewed and approved by the institu-
tional review board (IRB) or the independent medical ethics com-
mittee at each of the investigational centres. This study was ﬁnally
approved by the medical ethics committee of the Erasmus Medical
Centre (MEC 2011-505) and registered with ClinicalTrial.gov (pro-
tocol ID NCT 01847079). We used the CONSORT guideline to
construct our cluster-randomized trial (see Supplementary mate-
rial, Tables S1 and S2). All patients or their proxy provided written
informed consent before study inclusion, as a presumed consent at
ICU admission.
Patients on the ICU 18 years in whom a suspicion of infection
was raised and for whom taking blood for culture was clinically
indicated by the attending intensivist were enrolled in the study.
Suspicion of infection could be increasing body (tympanic) tem-
perature >38.3C, chills, progressive leucocytosis or increased C-
reactive protein, increasing consolidations on chest radiography or
other imaging of potential infection sources. Patients could be
included more than once; every time that blood for culture is taken
counts as a suspicion-of-infection episode (SIE). Patients were
excluded if they had one of the following exclusion criteria: preg-
nancy, neutropenia (deﬁned as leucocyte count <0.5  109/L) and
pre-terminal illness with an expected death within 24 hours. Pa-
tients were not included if blood cultures were performed as part of
a standard protocol (such as patients with veno-venous or veno-
arterial extracorporeal membrane oxygenation) or were per-
formed to check the effectiveness of treatment (such as in endo-
carditis), unless the blood culture was performed because of an SIE.
A ﬂow chart of the included patients is given in the Supplementary
material (Fig. S1). Patients were otherwise taken care of by board-
certiﬁed intensivists, according to local and national guidelines. In
case of a microbial infection source control was performed when
possible and antibiotic treatments were given in close collaboration
with a medical microbiologist.
Study protocol
The participating ICUs (two per medical centre) were stratiﬁed
and randomized by treatment regimen into a control group (stan-
dard of care) and a procalcitonin-guided group. Randomizationwas
performed per cluster allocation, being an assigned ICU. The
stratiﬁed randomization and enrolment of patients was performed
by one of the investigators. All patients included into this trial
followed the regimen that was allocated to the ICU for that period.Please cite this article in press as: van der Geest PJ, et al., Procalcitonin
randomized controlled trial, Clinical Microbiology and Infection (2016), hThe participating units switched the allocated regimen every
3 months. We used a wash-out period between the cross-over
period, to minimize the risk for a patient to follow two different
regimens. The wash-out period was set for 1 month, in which >99%
of the patients in the previous period have left the ICU. None of the
patients included in this study followed two regimens. The
participating ICUs were matched for a 1:1 ratio of allocation (see
Supplementary material, Fig. S2). No changes to methods or trial
outcomes have been made after trial commencement. The study
was stopped after achieving at least 550 inclusions based on the
power calculation.
In both the control and procalcitonin-guided groups blood was
taken at the same moment for the procalcitonin measurement and
blood cultures. In the control group, two sets of blood cultures were
sent directly to the medical microbiology department. The pro-
calcitonin measurement in the control group was determined by
the department of clinical chemistry, and results were blinded for
the investigators and only available before analysis. In the
procalcitonin-guided group the procalcitonin measurement was
determined as a stat determination, rendering results within
1 hour. Blood samples for the procalcitonin measurement were
immediately centrifuged at 3000 rpm for 10 minutes at room
temperature (Hettich Rotina 420R, Tuttlingen, Germany). The pro-
calcitonin measurement was performed on the automated Kryptor
platform (Brahms AG, Hennigsdorf, Germany), using the Roche
Elecsys Brahms procalcitonin assay. Upon receiving results, the
attending intensivists determined whether to send the blood cul-
tures to the medical microbiology department. We used a cut-off of
0.25 ng/mL in the procalcitonin-guided group. Values below this
cut-off were regarded as normal, and so not worth culturing (and
blood cultures taken were destroyed). It was possible for the
attending intensivists to overrule the procalcitonin-guided strategy
and still send in blood cultures at normal procalcitonin. For values
higher than the cut-off of 0.25 ng/mL, patients’ blood cultures were
sent to the medical microbiology department for further analysis.
Each set of blood cultures consists of one aerobic and one anaerobic
bottle (BD Bactec, Franklin Lakes, NJ, USA) containing resin to
enhance the recovery of organisms. The blood cultures were
incubated for 7 days in an automatic analyser (BD Bactec) that
automatically demonstrates the time to positive blood culture in
the case of positive bacterial or fungal growth. Gram strains were
performed, and the organisms were cultured on agar plates and
after growth identiﬁcation was performed, using the VITEK® 2
(Biomerieux, Marcy l'Etoile, France) for bacteria and the Auxacolor
(Sanoﬁ Diagnostics Pasteur, Lyon, France) for fungal growth. The
PCR technique was carried out using a LightCycler480 PCR system
(Roche Diagnostics, Almere, the Netherlands) to detect viral growth
in blood samples. Bacteraemia was deﬁned as having a positive
blood culture with a recognized pathogen except skin contami-
nants [18,19]. In the case of skin contaminants, bacteraemia was
only considered if at least two blood cultures drawn on separate
occasions were positive for the same microorganism [18,19]. We
otherwise determined inﬂammatory parameters such as C-reactive
protein (turbidimetric assay) and white blood cell counts (XN 9000,
Sysmex, Kobe, Japan).
Data collection
At the day of inclusion, baseline demographic data and clinical
variables, including age, sex, pre-morbidity, reasons of admission,
use of antibiotics excluding selective decontamination of the
digestive tract, antifungal treatment, steroids, immunosuppressive
medication, immune status (active malignancy or other causes of
an immunocompromised state), recent surgery, mechanical venti-
lation, renal replacement therapy, total parenteral nutrition, centralto guide taking blood cultures in the intensive care unit; a cluster-
ttp://dx.doi.org/10.1016/j.cmi.2016.10.004
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(n ¼ 288) (n ¼ 276)
Age (years) 59 (21) 61 (22) 0.36
Gender (male) 200 (69) 177 (64) 0.21
APACHE IV score 62 (36) 67 (45) 0.27
SOFA score 8 (6) 8 (6) 0.79
Pre-morbidity
Neurological 75 (26) 47 (17) 0.02
Cardiac 95 (33) 91 (33) 0.99
Pulmonary 66 (23) 50 (18) 0.11
Gastrointestinal 89 (31) 91 (33) 0.60
Renal 37 (13) 28 (10) 0.26
Diabetes mellitus type 2 55 (19) 47 (17) 0.45
Cancer 63 (22) 77 (28) 0.08
Autoimmune 14 (5) 14 (5) 0.93
Steroids 46 (16) 50 (18) 0.57
Immune suppression 20 (7) 22 (8) 0.64
Reasons of ICU admission 0.70
Suspected sepsis 86 (30) 83 (30)
Respiratory failure 54 (19) 61 (22)
Renal failure 1 (1) 2 (1)
Liver failure 0 2 (1)
Neurology 35 (12) 26 (9)
Cardiopulmonary resuscitation 14 (5) 14 (5)
Shock 12 (4) 7 (3)
Trauma 17 (6) 14 (5)
Postoperative 55 (19) 58 (21)
Miscellaneous 14 (5) 9 (3)
Treatment in ICU
Mechanical ventilation 245 (85) 246 (89) 0.15
Renal replacement therapy 63 (22) 69 (25) 0.44
Extra corporeal membrane
oxygenation
9 (3) 3 (1) 0.09
Central venous catheter 210 (73) 179 (65) 0.04
Norepinephrine 225 (78) 232 (84) 0.07
Antibiotics 279 (97) 270 (98) 0.32
Total parenteral nutrition 86 (30) 99 (36) 0.13
Length of ICU stay (days) 10 (17) 12 (20) 0.21
Length of hospital stay (days) 23 (35) 31 (39) 0.005
Numbers (percentage) or median (interquartile range), where appropriate.
Abbreviations: APACHE IV, Acute Physiology and Chronic Health Evaluation II; ICU,
intensive care unit; PCT, procalcitonin; SOFA, sequential organ failure assessment
score.
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(n ¼ 554) (n ¼ 576)
Temperature (C) 38.1 (1.6) 38.0 (1.6) 0.14
Heart rate (beats/min) 109 (32) 111 (32) 0.11
Respiratory rate (breaths/ min) 30 (16) 28 (18) 0.97
White blood cell count (109/L) 12.6 (9.7) 12.5 (9.9) 0.40
C-reactive protein (mg/L) 111 (147) 148 (178) <0.001
Procalcitonin (mg/L) 1.1 (5.2) 1.4 (6.1) 0.18
Median (interquartile range).
P.J. van der Geest et al. / Clinical Microbiology and Infection xxx (2016) 1.e1e1.e6 1.e3venous catheters and vital parameters were recorded. The acute
physiology and chronic health evaluation IV (APACHE IV) and the
sequential organ failure assessment (SOFA) scores were recorded at
admission. Patients were followed until day 28 and day 90 after
inclusion and length of ICU stay and vital outcomes were recorded.
Statistical analysis
The primary outcome measurement of this study is safety,
expressed asmortality at day 28 and day 90.We calculated that 550
patients were needed to determine non-inferiority in a parallel
group design with a power of 90%, a one-sided a error of 5% and a
non-inferiority limit of 10% [20]. The sample size calculation was
based on an assumed risk of death of 20% in both the control and
intervention groups in procalcitonin-guided antibiotic studies
[21e24]. A hierarchical Poisson regression model, using the loga-
rithm of the survival time as an offset variable, was used to estimate
the relative risk of mortality and associated 95% CI between control
and procalcitonin-guided groups. The ward and ward-period
interaction were used as random effects to account for systematic
effects of ward and period on the outcome [25]. The results were
deemed non-inferior when the 95% CI was <1.20 (non-inferiority
limit 20%) as our design was more complicated than a parallel
group design and had precluded a power analysis based on Poisson
regression. We performed an intention-to-treat analysis (all
procalcitonin-guided versus control patients), per-protocol analysis
(procalcitonin-guided patients without blood cultures versus con-
trols), and an as-treated analysis (procalcitonin-guided patients
without blood cultures versus procalcitonin-guided patients with
blood cultures and controls). All analyses were performed using R
version 3.2.1 and the hierarchical Poisson models were ﬁtted using
the lme4 package. Data are expressed as median (interquartile
range) or as number of patients (percentage) where appropriate.
Indeed, data were distributed non-normally (Kolmogor-
oveSmirnov test, p <0.05). The ManneWhitney U test and Fisher
exact test were used to compare two groups. Analysis of variance
was used to compare repeatedmeasurements between two groups.
All tests were two-sided, and p <0.05 was considered statistically
signiﬁcant. Exact p values >0.001 are given.
Results
Descriptives
In total, 1448 patients were possibly eligible for inclusion, of
whom 564 were included and remained for analysis (Fig. S1). The
control group consisted of 288 patients and the procalcitonin-
guided group comprised 276 patients (Table 1). No difference was
observed between the groups, except for more neurological pre-
morbidity in the control group (Table 1).
Suspected infection episodes
Table 2 shows that the control group represented 554 SIE
against 576 SIE in the procalcitonin-guided group,with a somewhat
higher C-reactive protein in the latter. In the control group there
were 118 episodes of bacteraemia in 58 patients, against 156 epi-
sodes in 63 patients in the procalcitonin-guided group (Table 3). In
only six episodes of bacteraemia the procalcitonin value was >0.25
ng/mL (three Enterococcus faecalis, one Enterococcus faecium, one
Staphylococcus aureus and one Staphylococcus epidermidis). The
genus of the micro-organism cultures in the other 268 episodes
were: 99 staphylococci, 39 streptococci, 88 Enterobacteriaceae,
seven Bacteroides, ﬁve Bacillus, two Burkholderia, six Pseudomonas
and 24 fungi and four viruses.Please cite this article in press as: van der Geest PJ, et al., Procalcitonin
randomized controlled trial, Clinical Microbiology and Infection (2016), hPrimary outcome
No difference was seen in 28-day or 90-day mortality between
the groups (Table 3). The 28-day and 90-day mortality rate in the
procalcitonin-guided group was 29% (80/276) and 38% (105/276),
respectively. The mortality rate in the control group was 32% (92/
288) at day 28 and 40% (115/288) at day 90. The intention-to-treat
analysis showed hazard ratios of 0.85 (95% CI 0.62e1.17) and 0.89
(95% CI 0.67e1.17) for 28-day and 90-day mortality, respectively,
favouring the procalcitonin-guided group. The per-protocolto guide taking blood cultures in the intensive care unit; a cluster-
ttp://dx.doi.org/10.1016/j.cmi.2016.10.004
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(n ¼ 288) (n ¼ 276)
Mortality day 28 92 (32) 80 (29) 0.36
Mortality day 90 115 (40) 105 (38) 0.53
PCT <0.25 and no BC sent in (n ¼ 0) (n ¼ 17)
Mortality day 28 d 5 (29) d
Mortality day 90 d 6 (35) d
PCT <0.25 and BC sent in (n ¼ 57) (n ¼ 20)
Mortality day 28 11 (19) 4 (19) 0.57
Mortality day 90 15 (26) 6 (29) 0.65
PCT >0.25 and BC sent in (n ¼ 231) (n ¼ 239)
Mortality day 28 81 (35) 71 (30) 0.20
Mortality day 90 100 (43) 93 (39) 0.27
Abbreviations: BC, blood culture; PCT, procalcitonin.
P.J. van der Geest et al. / Clinical Microbiology and Infection xxx (2016) 1.e1e1.e61.e4analysis showed hazard ratios of 0.89 (95% CI 0.67e1.17) and 0.89
(95% CI 0.67e1.17) for 28-day and 90-day mortality, respectively.
The as-treated analysis showed hazard ratios of 0.89 (95% CI
0.67e1.17) and 0.89 (95% CI 0.67e1.17) for 28-day and 90-day
mortality, respectively. The results were deemed non-inferior
because the upper limit of the 95% CI was below the margin of
1.20. The length of ICU stay was comparable between groups, but
the length of hospital stay was longer in the procalcitonin-guided
group (Table 1).
Predictive values
Procalcitonin <0.25 ng/mL occurred in 121 and 76 SIEs in the
control and procalcitonin-guided groups, respectively (Table 4). The
sensitivity of a low procalcitonin for predicting bacteraemia was
98% with a speciﬁcity of 20%, negative predictive value 96% and
positive predictive value 29%. Most patients were treated with
antibiotics already at SIE I, without differences between
procalcitonin-guidance and control groups.
Discussion
This study evaluated the predictive value of procalcitonin for
bacteraemia and the safety of withholding blood cultures in criti-
cally ill patients with an SIE but a normal procalcitonin. Based onTable 4
Procalcitonin measurements and blood culture results for the different suspicion-of-infe
SIE I
Control group Procalcitonin-group
(n ¼ 288) (n ¼ 276)
Number (percentage) of blood cultures taken 288 (100) 259 (94)
Positive blood cultures 71 (25) 70 (25)
PCT <0.25 ng/mL and BC negative 47 (16) 15 (5)
PCT <0.25 ng/mL and BC contamination 8 (3) 4 (1)
PCT <0.25 ng/mL and BC positive 2 (1) 1 (1)
PCT 0.25 ng/mL and BC negative 170 (59) 174 (63)
PCT 0.25 ng/mL and BC contamination 4 (1) 3 (1)
PCT 0.25 ng/mL and BC positive 57 (20) 62 (22)
On antibiotics
PCT <0.25 ng/mL and BC negative 43 (91) 30 (94)
PCT <0.25 ng/mL and BC contamination 8 (100) 4 (100)
PCT <0.25 ng/mL and BC positive 2 (100) 1 (100)
PCT 0.25 ng/mL and BC negative 167 (98) 171 (98)
PCT 0.25 ng/mL and BC contamination 4 (100) 3 (100)
PCT 0.25 ng/mL and BC positive 57 (100) 62 (100)
Abbreviations: BC, blood culture; PCT, procalcitonin; SIE, suspicion of infection episode.
Please cite this article in press as: van der Geest PJ, et al., Procalcitonin
randomized controlled trial, Clinical Microbiology and Infection (2016), hthe high negative predictive value and the regression analyses,
without exceeding a 20% group difference for mortality, a low
procalcitonin can be safely used to rule out bacteraemia, but the
beneﬁts may be limited.
This study suggests that a procalcitonin-guided algorithm for
performing blood cultures can be safely applied. The overall ICU
mortality rate was 27% (30% control group versus 24%
procalcitonin-guided group) and the overall in hospital mortality
rate was 35% (38% control group and 33% procalcitonin-guided
group), which agrees with an international study of the preva-
lence and outcomes of infection in ICUs [5] and a large systematic
review and meta-analysis on procalcitonin-guided antibiotic ther-
apy in critically ill patients with bacteraemia [22]. The longer length
of hospital stay in the procalcitonin-guided group could be
explained by a transfer delay from the regular ward.
The observed occurrence of bacteraemia in this study varies
between 20% and 23%, which is comparable with a recently per-
formed meta-analysis on the diagnostic accuracy of procalcitonin
for bacteraemia [9]. In the current study we have chosen to use a
cut-off value of 0.25 ng/mL for procalcitonin, which was based on
two previous studies that looked at the predictive value of pro-
calcitonin for bacteraemia in patients in the emergency department
[26,27]. With the used cut-off of 0.25 ng/ml we found a sensitivity
of 98% and a speciﬁcity of 20% for the prediction of bacteraemia.
Other studies performed on the diagnostic accuracy of procalcito-
nin for bacteraemia in the critically ill used a cut-off value of 0.5 ng/
ml [6,10e17]. By using a cut-off of 0.5 ng/ml we found a sensitivity
of 86% and speciﬁcity of 32% for the prediction of bacteraemia. The
results are comparable with other studies on the diagnostic accu-
racy of procalcitonin for bacteraemia [6,10e17]. The corresponding
negative and positive predictive values at a cut-off value of 0.25 ng/
ml are 96% and 29%, respectively, and are comparable with the
observed negative predictive value of 98% and positive predictive
value of 28% in a large meta-analysis [9].
A total of 1130 blood cultures were taken in this study, of which
197 (17%) could have been saved by using procalcitonin as a pre-
test. The value is much lower compared with two other studies,
which predicted a possible reduction of 37%e40% of blood cultures
[26,27]. Both studies, only designed to evaluate predictive values,
used a cut-off of 0.25 ng/mL and described sensitivities of 96% and
94%, respectively, which are comparable with our study [26,27].
The observed difference could be explained by the fact that both
studies were performed on the emergency department or primary-ction episodes
SIE II SIE III and IV
Control group Procalcitonin-group Control group Procalcitonin-group
(n ¼ 149) (n ¼ 127) (n ¼ 117) (n ¼ 173)
149 (100) 126 (99) 117 (100) 173 (100)
43 (29) 37 (29) 37 (32) 62 (36)
24 (16) 15 (12) 25 (21) 17 (10)
6 (4) 2 (2) 7 (6) 3 (2)
1 (1) 1 (1) 1 (1) 0
82 (55) 74 (58) 55 (47) 94 (54)
1 (1) 0 7 (6) 1 (1)
35 (23) 34 (27) 22 (19) 58 (33)
24 (100) 16 (100) 25 (100) 17 (100)
6 (100) 2 (100) 7 (100) 3 (100)
1 (100) 1 (100) 1 (100) 0
81 (99) 74 (100) 55 (100) 94 (100)
1 (100) 0 7 (100) 1 (100)
35 (100) 34 (1000) 22 (100) 58 (100)
to guide taking blood cultures in the intensive care unit; a cluster-
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tract infection or pneumonia. This contrasts with our study, which
was performed in critically ill patients, in which a suspected
infection can be proven in only 50% or less.
With the used cut-off, procalcitonin classiﬁed 143 SIEs correctly
for not having bacteraemia (true negative) and classiﬁed six SIEs
false for not having bacteraemia (false negative). In the latter cases,
the cultured microorganisms were susceptible to antibiotics and
patients were treated with vancomycin or ﬂucloxacillin in the case
of cultured staphylococci and enterococci. Arterial and central
venous catheters were replaced. The question remains if we would
have missed cases of severe bacteraemia by using the procalcitonin
strategy and destruction of all blood cultures at low procalcitonin
and whether this would have harmed patients. Many experts
favour deferring antimicrobial therapy for a bacteraemia caused by
Enterococcus spp. in the setting of a single positive blood culture,
because catheter removal alone may be sufﬁcient to cure the
infection in patient where the intravascular catheter is the likely
source of bacteraemia [8,28,29]. In the four cases of enterococcal
bacteraemia in this study only a single blood culture was positive
and the four cases could be regarded as low-grade infection in
which removal of indwelling catheters could have been sufﬁcient
treatment. The other two cases of staphylococcal bacteraemia
should be regarded as true bacteraemia, which would have been
falsely classiﬁed as having no bacteraemia if cultures had been
destroyed. In the case of Staphylococcus epidermidis, three sets of
blood cultures were even positive. Anyway, clinical judgement
should always predominate over procalcitonin determinations,
including reasons for catheter removal and culture.
This study has several limitations. First of all, in only 17 (46%)
patients with low procalcitonin levels, blood cultures were saved in
the procalcitonin-guided group. When the protocol had been
strictly followed, blood cultures could have been saved in 76 SIEs,
for which a classic intention-to-treat analysis could be performed.
However, we used a hierarchical approach as described by Chris-
tiansen and Morris, having several advantages such as removal of
regression to the mean bias and the use of smaller sample sizes in
the analysis [25]. In case of non-compliance a per-protocol analysis
is as important as an intention-to-treat analysis. Therefore we
provided a per-protocol and an as-treated analysis next to the
intention-to-treat analysis. The different analyses showed no dif-
ferences in hazard ratios, thereby suggesting that a procalcitonin-
guided strategy could be safely performed in clinical practices.
However, the mortality rates could have been higher in the
procalcitonin-guided group in case the protocol was strictly fol-
lowed, which suggests that a procalcitonin-guided strategy cannot
be safely performed. Second, the intensity and standard of clinical
care could have been affected, as this study was single-blinded and
the attending intensivists were aware that the intervention was
taking place. Third, for the primary sample size calculation of this
study we used a non-inferiority limit of 10% by parallel group
design, as an a priori power analysis based on Poisson regression
appeared hardly possible, we decided to use a non-inferiority limit
of 20% for ﬁnal analysis by Poisson regression. A non-inferiority
limit is usually set at 10%e20%, but choosing a non-inferiority
limit remains difﬁcult and debatable [30].
In the current study we demonstrated that PCT could be used to
save blood cultures in critically ill patients suspected of infection.
Using this strategy does not affect the prompt start of antibiotics in
a patient suspected of a serious infection, neither does this strategy
inﬂuence the time for a blood culture to become positive, as there is
only a maximum delay of 1 hour. It may not limit overtreatment
with antibiotics, however, unless it is decided upon to limit anti-
biotics at a low procalcitonin, which was not the purpose of the
study. Nevertheless, most procalcitonin results in this study werePlease cite this article in press as: van der Geest PJ, et al., Procalcitonin
randomized controlled trial, Clinical Microbiology and Infection (2016), hobtained within 30 minutes, allowing in any case a timely admin-
istration of antibiotics if deemed necessary on clinical grounds. For
de-escalation of antibiotics, local cultures should remain available
when blood cultures are (presumably) negative.
Conclusion
In conclusion, this prospective multicentre randomized trial
showed that using a procalcitonin-guided strategy to obtain blood
cultures in critically ill patients with a suspicion of infection seems
to be safe, though the beneﬁts may be limited.
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